Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2020)
Historic Enterprise Value for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to -$18.0 million.
- Monopar Therapeutics' Enterprise Value fell 30010.04% to -$18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$18.0 million, marking a year-over-year decrease of 30010.04%. This contributed to the annual value of -$13.2 million for FY2019, which is 9170.7% down from last year.
- As of Q3 2020, Monopar Therapeutics' Enterprise Value stood at -$18.0 million, which was down 30010.04% from -$12.5 million recorded in Q2 2020.
- Monopar Therapeutics' Enterprise Value's 5-year high stood at -$2.9 million during Q4 2016, with a 5-year trough of -$18.0 million in Q3 2020.
- For the 5-year period, Monopar Therapeutics' Enterprise Value averaged around -$8.4 million, with its median value being -$7.9 million (2018).
- Per our database at Business Quant, Monopar Therapeutics' Enterprise Value skyrocketed by 4100.31% in 2019 and then tumbled by 30010.04% in 2020.
- Quarter analysis of 5 years shows Monopar Therapeutics' Enterprise Value stood at -$2.9 million in 2016, then plummeted by 240.48% to -$9.8 million in 2017, then rose by 29.54% to -$6.9 million in 2018, then crashed by 91.71% to -$13.2 million in 2019, then plummeted by 36.09% to -$18.0 million in 2020.
- Its Enterprise Value was -$18.0 million in Q3 2020, compared to -$12.5 million in Q2 2020 and -$12.6 million in Q1 2020.